Loading
A phase 1 trial of PTM-101 run by PanTher Therapeutics, now recruiting.
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) is a phase 1 interventional study registered as NCT06673017 by PanTher Therapeutics, with 26 participants planned, started 2025-04-14. Conditions recorded: Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma and Pancreatic Cancer. Interventions recorded: PTM-101.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/